



# Σ eureka

## eHealth Call for R&D Project Proposals Switzerland - Netherlands

**Call opening on February 4, 2021**

**Online information and project building event – February 24, 2021**

**Submission Project Outline by April 30, 2021**

**Submission Full project proposal by August 2, 2021**

**Project start by November 1, 2021**

### Background

EUREKA is an international co-operation programme supporting collaborative market oriented research and development projects that develop innovative products, processes and services. It is a decentralised network facilitating the coordination of national funding on R&D&I, the driving force of innovation in Europe for over 35 years. Switzerland and the Netherlands collaborate continuously among the 45 EUREKA member states and support all innovation topics with suitable EUREKA instruments (EUREKA Network, EUREKA Cluster and Eurostars projects).

Switzerland and the Netherlands are jointly announcing a bilateral call for project proposals. The call is managed in line with the EUREKA initiative ([www.eurekanetwork.org](http://www.eurekanetwork.org)) by the national EUREKA offices Innosuisse and Netherlands Enterprise Agency, in cooperation with the Dutch Top Sector Life Sciences and Health (Health~Holland) and the Swiss Federal Office for Public Health.

The present call for project proposals is connected to the Dutch-Swiss long-term strategies in public health laid down in the [The Federal Council's health policy strategy 2020–2030](#) and the [Dutch Knowledge & Innovation Agenda \(KIA\) on Health and Care 2020–2023](#). Both countries agree to allow international cooperation in fields of common strategic – that's is: scientific, societal and economic – interest for both countries.

Preliminary work of the Embassy of the Kingdom of the Netherlands in Switzerland showed that complementarities between the Netherlands and Switzerland exist in the field of digital health and revealed opportunities for collaboration. There is a common interest in promoting the use of 'real life' data and digital technologies to assist citizens, in particular children and their relatives, adolescents in the primary/secondary school context and their families, manage their individual health via self- and especially joint-management and contribute to improving population health, especially those living in low economic status neighbourhoods. This is the thematic area for the present pilot call.

Switzerland and the Netherlands strive for a small number of complementary and high-impact R&D projects. Therefore, both countries encourage and support the forming of appropriate interdisciplinary **public-private consortia** including key stakeholders and specialised organisations and the proper experimental contexts in both countries.

## **Scope**

The primary focus of this call will be on **stimulating application-driven research and development of technologies and innovations that allow children and adolescents in the primary/secondary school context, as well as their families and (in)direct relatives, to gain insight into their own health, related to their daily functioning and (inter)related determinants, manage their health and daily functioning and contribute to health research (i.e. citizen science) through the use of health (related) data ("quantified self"-approach<sup>1</sup>), with a view to improving both individual and population health (for instance via a personalized individual ePartner<sup>2</sup>).**

In order to create sustainable impact, open innovation and use of 'real world' data by involvement of public (schools, children and municipalities) and private partners are prerequisites for collaboration. Applications must elaborate the transfer of the results to the market and the benefit for participating companies. Funded consortia are strengthened by monitoring of joint progress and concrete deliverables across projects and organising knowledge exchanges between the consortia.

## **Participation and application**

The call is set up in 3 steps:

### **1. Online information and project building, February 24, 2021**

Potential applicants are invited to participate at the online information event, February 24, 2021. In this information session the scope and ambition of this joint call is further explained. Swiss and Dutch participants are invited to participate and to explore the possibilities for Swiss-Dutch collaborations. The agenda and registration will soon be available on <https://ehealth-call-ch-nl.b2match.io>.

The quality of the project and consortium is essential for its success. Organisers recommend to register their profiles on the online matchmaking platform <https://ehealth-call-ch-nl.b2match.io>. The platform offers a marketplace, where project ideas, cooperation offers or requests etc. can be exchanged with the ambition to find synergies, cluster and select and integrate project ideas where possible and relevant. This interactive platform is the starting point of co-creating project proposals for high impact R&D projects and remains open for the whole duration of the call until 2 August 2021.

### **2. Submission project outline by April 30, 2021**

NL-CH consortia are encouraged to draft a project outline fitting the scope of this call before Friday April 30, 2021, 17:00 (CEST). The completed project outlines should be submitted to the national EUREKA offices, Innosuisse and Netherlands Enterprise Agency. Application details can be found below. The outlines will be screened by the two EUREKA offices, Health~Holland and the Federal Office for Public Health. Consortia will be provided with detailed feedback and most promising projects are invited to prepare adjusted full project proposal. If applicable, applicants can be invited to integrate their project with other submitted initiatives. If necessary, applicants receive recommendations on which of the other (EUREKA) funding mechanisms best/better fit their project idea.

### **3. Submission full project proposal by August 2, 2021**

After feedback on the project outlines, consortia are invited to submit a full proposal and apply for funding before Friday August 2, 2021, 17:00 (CEST). The full project proposals should be submitted to the national EUREKA offices, Innosuisse and Netherlands Enterprise Agency. Application details can be found below. The proposals are evaluated by

---

<sup>1</sup> Quantified self is the act of using personal data to improve one's quality of life. Self-tracking and self-experiment; sharing first person reports about our own discoveries using our own data.

(<https://quantifiedself.com/>)

<sup>2</sup> An ePartner is an interactive, virtual or embodied computer assistant to which one can communicate and that assists persons through tailored advice, coaching and support.

([https://www.tno.nl/media/2200/epartners\\_supporting\\_behavior\\_change.pdf](https://www.tno.nl/media/2200/epartners_supporting_behavior_change.pdf))

Health~Holland (supported by Netherlands Enterprise Agency) and Innosuisse based on their national funding criteria and conditions.

## Financing

Funding support to approved full project applications will be given to each partner by its own national funding organization in accordance with the national laws, rules, regulations and procedures in effect.

In the Netherlands, Health~Holland has allocated a budget of € 1.000.000.

In Switzerland, Innosuisse has allocated a budget of ~ € 1.000.000

## Eligibility

In order to apply for this call, applications must meet the following EUREKA and national eligibility criteria:

- The R&D project must fit the scope of the call.
- The R&D project fits within the Dutch societal challenge 'Health & Care', as outlined in the [Knowledge and Innovation Agenda 2020-2023](#)
- The R&D project fits within the Swiss Federal Council's [health policy strategy 2020-2030](#)
- The consortium includes at least one independent partner from Switzerland and one independent partner from the Netherlands;
- The consortium includes at least one (for profit) company, one public partner (schools, municipalities, etc.) and one research institute from the Netherlands and Switzerland;
- In the project activities there must be technological risk involved (industrial research and/or experimental development);
- The project must be directed at researching or developing a (set of) product(s), process(es) or service(s);
- The project must benefit all project partners in a well-balanced consortium and the project is significant to the health strategies in both countries involved;
- The project has an obvious advantage and added value resulting from the cooperation between the participants from the different countries (e.g. increased knowledge base, commercial leads, access to data, R&D infrastructure, etc.);
- Collected and/or generated data should comply with the FAIR principles. Data and code used and/or developed in the project should be shared, accessible for all consortium partners. A data management and stewardship plan is mandatory (drawn up if application is awarded for funding)
- The duration of the project may not exceed 36 months.

On national level additional eligibility criteria may apply. Applicants are strongly advised to inform national contact point and check if additional national eligibility criteria are applicable.

A signed consortium agreement on the execution of the project and the commercialisation of the projects results is mandatory before the actual start of the project. The consortium agreement should include, amongst others, the ownership and use of the know-how and IPR agreements. Project partners should take appropriate measures to protect intellectual property rights arising from the cooperation projects under the framework of this call and in line with national legislations and international agreements in force.

## Evaluation criteria

### International EUREKA criteria

- Impact
  - o Is the market properly addressed in terms of size, access and risk?
  - o Is the value creation in terms of growth, employment, environmental and societal benefits properly addressed?
  - o What would be the competitive advantages resulting from the project?
  - o Are the commercialization plans clear and realistic?
- Excellence
  - o What is the degree of innovation?
  - o How is the new knowledge going to be used?
  - o Is the project challenging scientifically, technically and for the partners?
  - o Are technical achievability & risks conveniently addressed?
- Quality & efficiency of the implementation
  - o Quality of the consortium
  - o Is there added value through international co-operation?
  - o Are project management & planning realistic and clearly defined?
  - o Is the cost structure reasonable?

### Additional criteria CH and NL

The project partners should demonstrate:

- Complementary technological and societal excellence and qualifications.
- Strong base of partnership and aim for continuing collaboration even beyond the project duration.
- Management ability to successfully carry out the project and implement the results.
- Mutual advancement of implementing solutions in the relevant environment with a clear benefit for the target group, namely children and adolescents in the primary/secondary school context, as well as their families and (in-)direct relatives.
- Mutual advancement of R&D through the transfer of knowledge and expertise.

## **Application procedures**

### **Project outline, submission deadline Friday April 30, 2021, 17:00 (CEST)**

- Consortia have to submit a Project Outline, which can be downloaded from Innosuisse and Netherlands Enterprise Agency websites. The form must be completed in English. Swiss partners add a simplified Innosuisse application form to the Joint Call document (download from Innosuisse website).
- The completed project outlines should be submitted to the national EUREKA offices simultaneously **by email** to contact persons at Innosuisse and Netherlands Enterprise Agency, with copy to all partners of the consortium. Submission deadline is April 30, 2021, 17:00 (CEST).
- The project outlines will be screened by the two EUREKA offices, Health~Holland, Innosuisse experts and the Federal Office for Public Health. Consortia will be provided with detailed feedback within the shortest possible delay after the submission (about 2 weeks). Qualified consortia will be invited to submit a full project proposal. If applicable, applicants can be invited to integrate their project with other submitted initiatives. If necessary, applicants receive recommendations on which of the other (EUREKA) funding mechanisms best/better fit their project idea.

### **Full project proposal, submission deadline Friday August 2, 2021, 17:00 (CEST)**

- After feedback on the project outlines, consortia are invited to submit a full proposal.
- The completed full proposals must be submitted before August 2, 2021, 17:00 (CEST) as follows:
  - o International EUREKA project form:  
All partners must complete the online Eureka project form. The form must be completed in English. More detailed instructions will be communicated once feedback on project outlines is given.
  - o National applications:  
In parallel to the completion of the Eureka project form, all project partners are required to submit a related national funding application to their respective funding agencies, taking into account all relevant procedures and submission rules described in the chapter "National funding conditions". More detailed instructions will be communicated with the invitation to submit a full project proposal.
- The full project proposals will be evaluated by Innosuisse and Health~Holland (with support of Netherlands Enterprise Agency). Preliminary national evaluation results are discussed during consensus meeting. Based on the national evaluation results both funders agree which projects to approve and recommend for funding. Final results are expected within 8 weeks after submission deadline.

## National funding conditions

### Switzerland

Swiss consortia members apply for funding at Innosuisse according to the following rules:

- Swiss academic partner and Swiss company or public organisation share costs of the project 50:50; Innosuisse may fund the share of the Swiss academic partner, i.e. up to 50% of eligible costs;
- Swiss academic partners are funded 100% by Innosuisse. Additionally, 10% of the funding costs of Innosuisse comes in form of a cash contribution (e.g. for material use by the research partner) from the Swiss company. Contributions of public (schools, children and municipalities) organisations are taken into account as in-kind contributions.
- Swiss companies get the right to exploit the project results in their specific business area and public (schools, children and municipalities) organisations will receive the full scientific documentation and recommendations to improve the health management of their target group.

### Netherlands

Dutch consortia members apply for funding at Health~Holland according to the following rules:

- The consortium consists of at least one for-profit enterprise and at least one research organisation.
- Research organisations and Small and Medium-sized Enterprises (SMEs) registered in the Netherlands are eligible for funding. The funding provided by Health~Holland are grants (50% for industrial research activities, 25% for experimental development activities)
- For this call Health~Holland requires minimum 30% contribution of project costs of (for-profit) enterprises in the consortium. This contribution can be in cash and/or in kind.
- Projects fit within the societal challenge 'Health & Care', as outlined in the [Knowledge and Innovation Agenda 2020-2023](#), and the objectives of the regulation.
- The project covers industrial research or experimental development, or a combination thereof. A description of the types of research is provided on [www.health-holland.com](http://www.health-holland.com).
- Effective collaboration takes place. The project will be realised at joint cost and risk and all consortium partners will make a substantive contribution to the project.
- The research is of a qualitatively high level and the innovative products and services are deliverables that have an added societal and economic value.
- The research project benefits the Dutch knowledge infrastructure and economy.
- Dutch companies get the right to exploit the project results in their specific business area and public (schools, children and municipalities) organisations will receive the full scientific documentation and recommendations to improve the health management of their target group.
- The project must start within six months after the national awarding letter was received.

### Please note!

The complete and detailed funding conditions for full project applications can be found on the respective websites of Innosuisse and Health~Holland, shortly after call launch.

## Contact

### Switzerland

#### **Innosuisse** ([www.innosuisse.ch](http://www.innosuisse.ch)):

Call management: Ms. Colette John, +41 58 466 77 32, [colette.john@innosuisse.ch](mailto:colette.john@innosuisse.ch)  
Matchmaking platform: Mr. Nicolas Lentze, +41 58 469 07 59,  
[nicolas.lentze@innosuisse.ch](mailto:nicolas.lentze@innosuisse.ch)

#### **Federal Office for Public Health** ([www.bag.admin.ch](http://www.bag.admin.ch))

Mr. Herbert Brunold, +41 58 463 88 03, [herbert.brunold@bag.admin.ch](mailto:herbert.brunold@bag.admin.ch)

### The Netherlands

#### **Netherlands Enterprise Agency** ([www.rvo.nl/eureka](http://www.rvo.nl/eureka)):

Call management: Mr. Niels van Leeuwen, +31 (0)6 52 56 33 10,  
[niels.vanleeuwen@rvo.nl](mailto:niels.vanleeuwen@rvo.nl)

Matchmaking platform: Ms. Michelle Lemmers, +31 (0)6 11 70 46 80,  
[michelle.lemmers@rvo.nl](mailto:michelle.lemmers@rvo.nl)

#### **Health~Holland** ([www.health-holland.com](http://www.health-holland.com)):

Ms. Jolande Zijlstra, +31 (0)6 24 92 68 82, [zijlstra@health-holland.com](mailto:zijlstra@health-holland.com)